BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Sep 18, 2025 • 13min
Sweden's Annoca announced a $46M raise last month to help move its first TCR-T program into the clinic for KRAS-driven pancreatic cancer. CEO Reagan Jarvis tells us about that work and more.
He describes the raise and the trial, which is an umbrella study that will test products against three different mutations. Plus, work on vaccines and a non-oncology cell therapy program, and partnership opportunities.
Sep 17, 2025 • 16min
Xspray Pharma makes protein kinase inhibitors that are amorphous, and therefore more soluble than current products. Dasynoc, its version of dasatinib (Sprycel), is in front of FDA with an Oct 7 PDUFA
CEO Per Andersson walks us through the benefits of designing kinase inhibitors this way, which should not be affected by the pH of the stomach. He shows us the unique manufacturing equipment, and walks us through a pipeline that includes dasatinib, nilotinib, axitinib, and cabozantinib.
Sep 16, 2025 • 9min
Pareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S.
CEO Nicklas Westerholm walks us through the condition, which is an X-chromosome linked rare disease that affects men, and he describes how the launch is going in Europe, and plans for an FDA meeting.
Sep 16, 2025 • 9min
Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to user in the next generation of acid reflux medicines with, linaprazan glurate, a potassium-competitive acid blocker (P-CAB)
CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated at AstraZeneca, though Cinclus owns it outright today, and is in a phase 3 that just started.
Sep 16, 2025 • 11min
Pareto Securities' Healthcare Conference: Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch in the region
He sees an optimistic turn after a challenging couple of years. Plus, highlighting Vicor, Camurus, Oculis, and BioArctic.
Sep 16, 2025 • 12min
Pareto Securities' Healthcare Conference: Saniona has built expertise in the ion channel space, in addition to its own work, it has partnerships with Jazz, Acadia, and others
CEO Thomas Feldthus describes the challenge of making ion channel medicines selective enough to avoid unwanted side effects. He walks us through the Jazz and Acadia partnership, and highlights three other internally developed programs.
Sep 16, 2025 • 12min
Pareto Securities' Healthcare Conference: BioArctic's CEO Gunilla Osswald highlights the company's brain transporter technology, the latest on Leqembi, and a Parkinson's program
She describes the transferrin receptor based brain transporter technology, which the company recently signed another new partner (Novartis) on for $30M up front. Plus, the European approval of Leqembi, and how the Parkinson's program is progressing.
Sep 16, 2025 • 9min
Pareto Securities' Healthcare Conference: Guard Therapeutics will have a key P2b trial read for its kidney protecting therapy RCM-035 in the 4th quarter - CEO Tobias Agervald walks us through it
He describes the science behind the A1M protein that this is based on, and how Guard has chosen kidney protection for patients who are undergoing heart surgery as the lead indication. We walk through various scenarios ahead of the upcoming readout.
Sep 16, 2025 • 9min
Pareto Securities' Healthcare Conference: BioInvent has recently optimized its pipeline to focus on two key programs - BI-1808, the anti-TNFR2 antibody, and BI-1206, an FcγRIIB inhibitor
CEO Martin Welschof walks us through these two programs, which both target liquid and solid tumors. BI-1808 recently had data at EHA and will have solid tumor data later this year, while 2026 will be data rich for BI-1206.
Sep 16, 2025 • 7min
Pareto Securities Healthcare Conference: Basilea is using its financial strength from two marketed products to develop its pipeline and acquire new products - it just received more BARDA funding today
CEO David Veitch walks us through the U.S. launch of Zevtera, and discusses where Cresemba is in its global commercial lifecycle. Plus, pipeline progress, and how Basilea's experience with BARDA funding has been a good sign of consistency for the field.
